Convergence : mensuel de la solidarité / Secours populaire français ; dir. publ. Julien Lauprêtre ; réd. Antonio Garcia, Valmont Ponceau

avril 20052005/04 (N247)-2005/04.Appartient à l’ensemble documentaire : UnivJeun

Rabies laboratory capacities.

<p>Percent of countries that replied positively to the use of various laboratory techniques for rabies diagnosis. Seventeen of 19 countries responded; the two non-responders included one low income and one upper middle income country.</p

Number of countries that completed the REDIPRA questionnaires by main group of indicators by year.

<p>No PEP application data was collected for 2007. No data was collected for 2010–2011.</p

Animal exposures and post-exposure-prophylaxis (PEP).

<p>(A) Number of animal exposures and number of human rabies vaccines applied by year, period 1998–2014; (B) Ratio PEP doses to number of exposures; (C) Incidence of exposures per 100,000 population.</p

Development of capacities against emerging and endemic zoonoses per country.

<p>Seven capacities were assessed for each country. Countries are grouped by sub-region (South America, Central and North America, and the Caribbean). The first bar shows the average capacity development for all countries that responded to the survey (31). Regional averages are also shown for each region to allow comparisons between countries.</p

Indicators of national program capability in 2013–2014.

<p>Percentage of country respondents (n = 19) in 2013–2014 with national rabies control programs and basic indicators for control programs.</p

Comparison between the Ministries regarding their top endemic zoonotic disease priorities.

<p>Comparison between the Ministries regarding their top endemic zoonotic disease priorities.</p

Dog vaccine expenditure for years 2013–2014 showing the average unit cost per dose and type of vaccine (Nerve Tissue Vaccines (NTV) vs. cell culture) as reported by the countries, the number of doses applied, and the estimated total expenditure on vaccine (only vaccine, not including logistics costs) for 16 LAC countries.

<p>Dog vaccine expenditure for years 2013–2014 showing the average unit cost per dose and type of vaccine (Nerve Tissue Vaccines (NTV) vs. cell culture) as reported by the countries, the number of doses applied, and the estimated total expenditure on vaccine (only vaccine, not including logistics costs) for 16 LAC countries.</p

List of endemic zoonotic diseases and their frequency in regards to their prioritization by the Ministries of Health and Agriculture and combined entities in Latin America and Caribbean countries.

<p>First, second, and third refer to the priority level of the zoonotic diseases and total is a sum of all the times that disease was prioritized in such categories.</p

Human and dog rabies cases in LAC countries reported to SIRVERA.

<p>(A) Human case counts since the beginning of regional elimination program, period 1983–2014. Data collection on aggressor species began in 1993 (vertical dashed line). Human cases from all aggressor species are represented with circles from 1983 and dog-mediated cases with triangles from 1993 onward. (B) Dog-mediated human case incidence per 100,000 population by income category (WB, 2014) at the tail end of the epidemic with Loess smoother, period 1998–2014. (C) Dog case counts since the beginning of regional elimination program, period 1983–2014. (D) Dog rabies incidence per 100,000 dogs by income category at the tail end of the epidemic, period 1998–2014, using reported dog population.</p